NIH- PRELIM RESULTS SUGGESTED A SURVIVAL BENEFIT, WITH A MORTALITY RATE OF 8.0% FOR GROUP RECEIVING REMDESIVIR VERSUS 11.6% FOR PLACEBO GROUP

PATIENTS WHO RECEIVED REMDESIVIR HAD A 31% FASTER TIME TO RECOVERY THAN THOSE WHO RECEIVED PLACEBO

$GILD $SPX